KAILERA THERAPEUTICS INC (KLRA)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$22.24-4.55%
Close 2026-07-07 · 1-day change
Reading KLRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track KLRA free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading KLRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track KLRA free→Intact: The reason to own it still holds.
Kailera is advancing gene therapies for rare diseases with strong clinical progress. It raised $600 million to fund its pipeline. Positive Phase 3 obesity trial data supports future product launches. New leadership may improve corporate strategy.
The company is still unprofitable with negative EPS expected through 2027. Recent earnings missed expectations. No revenue is currently forecasted, raising doubts about near-term commercial success.
The market is correcting with no clear consensus on revenue or earnings growth. Our view sees potential in clinical progress but acknowledges ongoing losses and execution risks.
Breaks if: failure to report positive Phase 3 data or significant trial delays in FY26
Breaks if: need for dilutive capital raise before end of 2027
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: no visible strategic progress or leadership instability in FY26
Breaks if: EPS loss worsens or remains flat beyond FY27